<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513370</url>
  </required_header>
  <id_info>
    <org_study_id>W10-151</org_study_id>
    <nct_id>NCT00513370</nct_id>
  </id_info>
  <brief_title>A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis</brief_title>
  <acronym>PRIDE</acronym>
  <official_title>A Canadian Open-Label Access Program to Evaluate the Safety and the Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when
      used for the treatment of subjects with active plaque psoriasis who have not adequately
      responded to prior psoriasis therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of &quot;Clear&quot; or &quot;Clear or Minimal&quot;</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Number of subjects achieving a response of &quot;Clear&quot; or &quot;Clear or Minimal&quot; on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>PASI 50/75/90/100 is a &gt;=50% / &gt;=75% / &gt;=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks</measure>
    <time_frame>16 and 24 weeks</time_frame>
    <description>Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on the EuroQol (EQ-5D) Quality of Life Questionnaire</measure>
    <time_frame>16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Productivity Outcomes and Costs From Baseline as Measured by the Health and Labour Questionnaire (HLQ)</measure>
    <time_frame>16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Resource Utilization Outcomes and Costs From Baseline as Measured by the Health Care Resource (HCR) Questionnaire</measure>
    <time_frame>16 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humira (adalimumab)</intervention_name>
    <description>Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>adalimumab</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a clinical diagnosis of psoriasis for at least 6 months prior to the
             Screening, as determined by subject interview of his/her medical history and
             confirmation of diagnosis through physical examination by the investigator

          -  Subject must have stable plaque psoriasis for at least 2 months prior to the
             Screening, as determined by subject interview of his/her medical history

          -  Subject has moderate to severely active plaque psoriasis at Baseline defined as: BSA
             (Body Surface Area) &gt; 10% and a Psoriasis Area and Severity Index (PASI) &gt; 12

          -  Subject has active psoriasis despite treatment with topical agents

          -  Subject has failed to respond to, is intolerant to or unable to access phototherapy

          -  Subject has failed to respond to, is intolerant to or has contraindication for at
             least two of the following therapies:

               -  CyA (Cyclosporine A)

               -  MTX (Methotrexate)

               -  Oral retinoid

          -  If female, subject is either not of childbearing potential, defined as postmenopausal
             for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral
             oophorectomy or hysterectomy), or is of childbearing potential and practicing one of
             the following methods of birth control:

               -  Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)

               -  Contraceptives (oral or parenteral) for three months (90 days) prior to study
                  drug administration

               -  A vasectomized partner

               -  Total abstinence from sexual intercourse

          -  If female and of childbearing potential, the result of a serum pregnancy test
             performed at Screening is negative

          -  Able and willing to self-administer sc injections or has available qualified person(s)
             to administer sc injections

          -  Able and willing to give written informed consent and comply with the requirements of
             the study protocol

        Exclusion Criteria:

          -  Subject has other active skin diseases or skin infections (bacterial, fungal, or
             viral) that may interfere with the evaluation of psoriasis or compromise the subject's
             safety

          -  Subject has erythrodermic psoriasis, generalized or localized pustular psoriasis,
             medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis
             as the primary morphology of their psoriasis

          -  Subject has a history of an allergic reaction or significant sensitivity to
             constituents of adalimumab

          -  Investigational agents not mentioned must be discontinued at least 30 days or 5
             half-lives prior to the Baseline visit (whichever is longer)

          -  Topical therapies:

               -  Subject started receiving a new topical therapy within the last four weeks prior
                  to the Baseline visit for areas other than the palms, soles of feet, axilla and
                  groin.

               -  Dose(s) and regimen(s) of topical therapy(ies) that the subject is receiving at
                  the Baseline visit, for areas other than the palms, soles of feet, axilla and
                  groin, was (were) increased during the four weeks that preceded the Baseline
                  visit.

               -  Subject is likely to require the initiation of a new topical therapy for the
                  treatment of psoriasis such as corticosteroids, vitamin D analogs, or retinoids
                  during the first 16 weeks that will follow the Baseline visit. (During the first
                  16 weeks that will follow the Baseline visit, initiation of topical therapies are
                  allowed for the palms, soles of feet, axilla and groin area only).

          -  Oral or injectable corticosteroids therapies:

               -  Subject started receiving oral or injectable doses of corticosteroids within the
                  last four weeks prior to the Baseline visit.

               -  Dose(s) and regimen(s) of corticosteroids therapy(ies) that the subject is
                  receiving at the Baseline visit, was (were) increased during the four weeks that
                  preceded the Baseline visit.

               -  Subject is likely to require the initiation of oral or injectable dose of
                  corticosteroids therapies for the treatment of psoriasis during the first 16
                  weeks that will follow the Baseline visit.

          -  Phototherapies

               -  Subject started being treated with UVB phototherapy, within the last four weeks
                  prior to the Baseline visit.

               -  Regimen(s) of concomitant UVB phototherapy that the subject is receiving at the
                  Baseline visit was (were) increased during the four weeks that preceded the
                  Baseline visit.

               -  Subject is likely to require the initiation of UVB therapy during the first 16
                  weeks that will follow the Baseline visit.

               -  Subject was treated with psoralen UVA (PUVA) phototherapy within the last four
                  weeks prior to the Baseline visit.

               -  Subject is likely to require PUVA phototherapy during the course of the study.

               -  Subject cannot avoid excessive sun exposure or the use of tanning booths for at
                  least 2 weeks prior to Baseline and during the first 16 weeks that will follow
                  the Baseline visit.

          -  Systemic Therapies:

               -  Subject has been initiated on a new systemic agent for the treatment of psoriasis
                  within the last four weeks prior to the Baseline visit.

               -  Dose(s) and regimen(s) of systemic therapy(ies) that the subject is receiving at
                  the Baseline visit, was (were) increased during the four weeks that preceded the
                  Baseline visit.

               -  Subject is likely to require the initiation of systemic therapy, other than
                  adalimumab, for the treatment of psoriasis during the first 16 weeks that will
                  follow the Baseline visit.

               -  Subject has been treated with systemic calcineurin inhibitors (cyclosporin, FK506
                  and others) within the last four weeks prior to the Baseline visit.

               -  Subject is likely to receive systemic calcineurin inhibitors during the course of
                  the study.

               -  Subject has received Anakinra/Kineret within the last 2 weeks prior to the
                  Baseline visit and is likely to receive Anakinra/Kineret during the course of the
                  study.

          -  Subject cannot discontinue the following systemic psoriasis therapies:

               -  Alefacept must be discontinued at least 12 weeks prior to the Baseline visit.

               -  Efalizumab must be discontinued at least 6 weeks prior to the Baseline visit.

               -  Infliximab must be discontinued at least 8 weeks prior to the Baseline visit.

               -  Etanercept must be discontinued at least 3 weeks prior to the Baseline visit.

          -  Subject has a history of cancer or lymphoproliferative disease other than:

               -  Successfully and completely treated Cervical dysplasia, with no recurrence within
                  the last five years.

          -  Has a history of uncontrolled diabetes, unstable ischemic heart disease, congestive
             heart failure, New York Heart Association (NYHA) III, IV, recent stroke (within three
             months), chronic leg ulcer and any other condition (e.g., indwelling urinary catheter)
             which, in the opinion of the Investigator, would put the subject at risk by
             participation in the protocol or who would make the subject unsuitable for the study.

          -  Positive serology for hepatitis B indicating acute or chronic infection.

          -  Currently taking or likely to begin anti-retroviral therapy at any time during the
             course of the study.

          -  Subject is known to have immune deficiency, history of human immunodeficiency virus
             (HIV) or is immunocompromised.

          -  Persistent or recurrent or severe infections requiring hospitalization or treatment
             with intra-venous (IV) antibiotics within 30 days, or oral antibiotics within 14 days,
             prior to Baseline.

          -  Female subjects who are pregnant or breastfeeding.

          -  Has a history of clinically significant drug or alcohol abuse in the last year.

          -  Previous diagnosis or signs of central nervous system demyelinating diseases (e.g.,
             optic neuritis, visual disturbance, gait disorder/ataxia, facial paresis, apraxia).

          -  History of active tuberculosis (TB), history of histoplasmosis or listeriosis.

          -  Has latent TB (positive purified protein derivative (PPD) skin test, two-step PPD when
             applicable, and chest X-ray indicative of TB) or has other risk factors for the
             activation of latent TB, e.g. previous exposure to TB, and has not initiated TB
             prophylaxis prior to the first adalimumab treatment. In either case, the Abbott
             Medical Advisor must be contacted before initiating the study treatment.

          -  Subjects will be excluded if the CXR is found to have changes suggestive of old healed
             tuberculous lesion (e.g. calcified nodule, fibrotic scar, apical or basilar pleural
             thickening etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Papp, MD PhD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>K. Papp Clinical Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fenwick</city>
        <state>Ontario</state>
        <zip>L0S 1C0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nepean</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1J 1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>August 21, 2009</results_first_submitted>
  <results_first_submitted_qc>October 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2009</results_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Isabel Pereira, Affiliate Project Manager</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab 40 mg Eow</title>
          <description>adalimumab 40 mg every other week (eow)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab 40 mg Eow</title>
          <description>adalimumab 40 mg every other week (eow)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks</title>
        <description>PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree</description>
        <time_frame>16 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks</title>
          <description>PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks</title>
        <description>Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks</title>
          <description>Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="7.55"/>
                    <measurement group_id="O2" value="-16.1" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks</title>
        <description>Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks</title>
          <description>Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.5" spread="23.63"/>
                    <measurement group_id="O2" value="-83.0" spread="23.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)</title>
        <description>Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)</title>
          <description>Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of &quot;Clear&quot; or “Clear or Minimal”</title>
        <description>Number of subjects achieving a response of &quot;Clear&quot; or &quot;Clear or Minimal&quot; on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of &quot;Clear&quot; or “Clear or Minimal”</title>
          <description>Number of subjects achieving a response of &quot;Clear&quot; or &quot;Clear or Minimal&quot; on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects achieving &quot;Clear&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects achieving &quot;Clear or Minimal&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks</title>
        <description>Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks</title>
          <description>Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="23.48"/>
                    <measurement group_id="O2" value="-20.9" spread="23.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response</title>
        <description>PASI 50/75/90/100 is a &gt;=50% / &gt;=75% / &gt;=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response</title>
          <description>PASI 50/75/90/100 is a &gt;=50% / &gt;=75% / &gt;=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects achieving PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects achieving PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects achieving PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects achieving PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks</title>
        <description>Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks</title>
          <description>Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="13.57"/>
                    <measurement group_id="O2" value="-8.7" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks</title>
        <description>Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks</title>
          <description>Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="5.35"/>
                    <measurement group_id="O2" value="-4.9" spread="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks</title>
        <description>Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks</title>
          <description>Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.9" spread="31.77"/>
                    <measurement group_id="O2" value="-19.3" spread="32.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks</title>
        <description>Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks</title>
          <description>Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="7.09"/>
                    <measurement group_id="O2" value="-10.1" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0</title>
        <description>Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0</title>
          <description>Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks</title>
        <description>Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.</description>
        <time_frame>16 and 24 weeks</time_frame>
        <population>Observed Cases - subjects with nonmissing values at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab 40 mg Eow - 16 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 16 timepoint</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab 40 mg Eow - 24 Weeks</title>
            <description>adalimumab 40 mg every other week - Week 24 timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks</title>
          <description>Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.</description>
          <population>Observed Cases - subjects with nonmissing values at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="6.56"/>
                    <measurement group_id="O2" value="-4.3" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on the EuroQol (EQ-5D) Quality of Life Questionnaire</title>
        <time_frame>16 and 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Productivity Outcomes and Costs From Baseline as Measured by the Health and Labour Questionnaire (HLQ)</title>
        <time_frame>16 and 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Resource Utilization Outcomes and Costs From Baseline as Measured by the Health Care Resource (HCR) Questionnaire</title>
        <time_frame>16 and 24 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab 40 mg Eow</title>
          <description>adalimumab 40 mg every other week (eow)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first publication and presentation of this Study shall reside with Abbott. No independent manuscript may be submitted for publication until the first manuscript has been accepted for publication or twelve (12) months after completion of Study at all sites, which ever occurs first.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Specialist</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

